This article first appeared on GuruFocus.

RxSight Inc (NASDAQ:RXST) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $25.28 million, and the earnings are expected to come in at -$0.38 per share. The full year 2025's revenue is expected to be $125.49 million and the earnings are expected to be -$1.23 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 2 Warning Sign with RXST.

Is RXST fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for RxSight Inc (NASDAQ:RXST) have declined from $141.39 million to $125.49 million for the full year 2025 and declined from $161.20 million to $133.91 million for 2026 over the past 90 days. Earnings estimates have declined from -$1.07 per share to -$1.23 per share for the full year 2025 and declined from -$0.98 per share to -$1.16 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, RxSight Inc's (NASDAQ:RXST) actual revenue was $33.64 million, which missed analysts' revenue expectations of $35.19 million by -4.42%. RxSight Inc's (NASDAQ:RXST) actual earnings were -$0.29 per share, which missed analysts' earnings expectations of -$0.24 per share by -20.83%. After releasing the results, RxSight Inc (NASDAQ:RXST) was down by -7.70% in one day.

Based on the one-year price targets offered by 8 analysts, the average target price for RxSight Inc (NASDAQ:RXST) is $9.00 with a high estimate of $11.00 and a low estimate of $8.00. The average target implies an upside of 3.57% from the current price of $8.69.

Based on GuruFocus estimates, the estimated GF Value for RxSight Inc (NASDAQ:RXST) in one year is $38.02, suggesting an upside of 337.51% from the current price of $8.69.

Based on the consensus recommendation from 11 brokerage firms, RxSight Inc's (NASDAQ:RXST) average brokerage recommendation is currently 3.1, indicating a \\"Hold\\" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.